-
Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL_Matthew Davids, MD, MMSc
41:32
-
Updates in Management for Relapsed and Refractory CLL_Nicole Lamanna, MD; #hemeupdates2022
19:49
-
Novel Agents in CLL_John Allan, MD; #hemeupdates2022
14:57
-
New Therapeutic Options in Frontline CLL_Richard Furman, MD; #hemeupdates2022
15:59
-
New therapeutic options in frontline CLL_Susan O'Brien, MD; #BeyondTheCongress
14:51
-
Novel agents in CLL_Nitin Jain, MD; #BeyondTheCongress
14:25
-
Updates in management for relapsed and refractory CLL_Jennifer Brown, MD, PhD; #BeyondTheCongress
14:29
-
Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting_Jennifer Woyach, MD_Matthew Davids, MD, MMSc
31:18
-
Nicole Lamanna, MD; Columbia University Irving Medical Center; 5Live #ASH21
11:27
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Javier Pinilla-Ibarz, MD, PhD; Moffit Cancer Center; 5Live #ASH21
12:43
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Jennifer Woyach, MD; Ohio State; 5Live #ASH21
5:16
Key insights from the 2021 Annual Hematology meeting in Atlanta
- Next Page